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Abstract
Copy number variants are amongst the most highly penetrant risk factors for psychopathology and
neurodevelopmental deficits, but little information about the detailed clinical phenotype associated with particular
variants is available. We present the largest study of the microdeletion and -duplication at the distal 1q21 locus, which
has been associated with schizophrenia and intellectual disability, in order to investigate the range of psychiatric
phenotypes. Clinical and cognitive data from 68 deletion and 55 duplication carriers were analysed with logistic
regression analysis to compare frequencies of mental disorders between carrier groups and controls, and linear mixed
models to compare quantitative phenotypes. Both children and adults with copy number variants at 1q21 had high
frequencies of psychopathology. In the children, neurodevelopmental disorders were most prominent (56% for
deletion, 68% for duplication carriers). Adults had increased prevalence of mood (35% for deletion [OR= 6.6 (95% CI:
1.4–40.1)], 55% for duplication carriers [8.3 (1.4–55.5)]) and anxiety disorders (24% [1.8 (0.4–8.4)] and 55% [10.0
(1.9–71.2)]). The adult group, which included mainly genetically affected parents of probands, had an IQ in the normal
range. These results confirm high prevalence of neurodevelopmental disorders associated with CNVs at 1q21 but also
reveal high prevalence of mood and anxiety disorders in a high-functioning adult group with these CNVs. Because
carriers of neurodevelopmental CNVs who show relevant psychopathology but no major cognitive impairment are not
currently routinely receiving clinical genetic services widening of genetic testing in psychiatry may be considered.
Introduction
The microdeletion and the microduplication at 1q21
(chr1: 146.57–147.39; GRCh37/hg19) are enriched in
patients with schizophrenia (OR estimate for the deletion:
5.2; for the duplication: 2.9)1 and in patients with intel-
lectual disabilities (ID)/developmental delay (DD) and
autism spectrum disorder (ASD) (OR estimate for the
deletion: 35; for the duplication: 18)2,3. The estimates for
the population frequency of the microdeletion and
-duplication at this locus derived from UK Biobank are
0.027% and 0.044%, respectively4 although this may
underestimate the true frequency in the population
because more severely affected carriers are likely to be
underrepresented in a middle-aged research cohort.
The clinical phenotype of 1q21 deletion5,6 and dupli-
cation6 was originally established in clinical cohorts with
intellectual disability, autism or congenital anomalies.
A systematic review of 22 studies containing data from
59 children and 48 adults with the 1q21.1 duplication7
reported high frequencies of neurodevelopmental pro-
blems including 50.8% for DD/ID, 35.6% for autism or
autistic features and 8.5% for seizures. In 2015, the
Simons VIP Consortium published a comparison of 19
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deletion carriers and 19 duplication carriers with familial
noncarrier controls8. Amongst deletion carriers, the most
prevalent neuropsychiatric features were mood and
anxiety disorders (26%) and seizures (18%), whereas the
predominant neuropsychiatric disorders in duplication
carriers were ASD (41%) and ADHD (29%). A major
limitation of the extant literature is that most studies have
had small sample sizes and few reports have included
detailed psychiatric phenotyping, and there is very little
detailed clinical data from adults. In the present multi-
centre study, we tripled the sample size compared to the
Bernier et al.8 study (123 compared to 38 CNV carriers,
also included in the present study). The aim of the current
study was to analyse psychopathology in the largest
international cohort so far assembled that comprises
carriers of the reciprocal microdeletion and –duplication
at 1q21 across children and adults. We specifically wanted
to ascertain whether mirror phenotypes—similar to the
established dose effect on head size6—also occur in the
psychological domain and whether—and what type of—
psychopathology was prevalent in an adult group largely
composed of family carriers and thus not affected by the
ascertainment bias of clinical samples.
Patients and methods
Participants were recruited by three research groups/
consortia: the Simons Variation in Individuals Project
(VIP) consortium (n= 51); the CNV Research Group,
Lausanne University Hospital, Lausanne, Switzerland
(n= 12); and the Neuroscience and Mental Health
Research Institute, Cardiff University, UK (n= 60).
Unaffected family members were recruited as control
participants (Simons VIP: n= 51; Lausanne: n= 10; Car-
diff: n= 9).
Study sample
Participants assessed in Cardiff were recruited by three
projects; children by the ‘Experiences of CHildren with
cOpy number Variants’ (ECHO) and ‘Intellectual Dis-
ability and Mental Health: Assessing the Genomic Impact
on Neurodevelopment’ (IMAGINE-ID, http://imagine-id.
org/)9 studies, and adults through the ‘Defining Endo-
phenotypes From Integrated Neurosciences’ (DEFINE)
study. Participants were given details of our study fol-
lowing a diagnosis of a 1q21.1 CNV at one of the UK
National Health Service genetics clinics. The study was
also advertised on support websites and social media
groups for carriers of 1q21.1 CNVs. Adult participants
were screened for the capacity to consent using a
telephone-based protocol. If they were deemed to lack
capacity, a personal consultee was contacted. All partici-
pants, or their personal consultee, provided informed
written consent. For participants under the age of 16,
parent/guardian consent and participant assent were
obtained. For 16–18-year-old participants consent was
obtained from participant and parent/guardian. All
interviews were taped and decisions on psychiatric
symptoms and diagnosis were made during consensus
meetings led by a psychiatrist. The South-East Wales
Research Ethics Committee approved the recruitment and
assessment protocols used in this study (14/WA/0035).
For the IMAGINE-ID study, protocols were approved by
the NHS London Queen Square research ethics com-
mittee (14/LO/1069).
Participants in the Simons VIP consortium were
ascertained clinically and recruited online and through
clinical laboratory referrals in the United States. Data
were collected at three participating U.S. sites. Further
details on the methods are available in Simons VIP,
201210. Participants with known additional clinically
recognized CNVs were excluded. Assessments were
standardized across sites through ongoing training and
inter-rater reliability checks. The study was approved by
the Institutional Review Boards at Columbia University
(AAAF3927), Geisinger Health System (2011-0320),
Children’s Hospital of Boston (12-009720), Baylor College
of Medicine (H-27549) and the University of Washington
(39149), and all participants 18 or older or the partici-
pant’s designated legal guardian provided written
informed consent (and children under 18 were assented,
when appropriate, based upon mental capacity).
Participants from the CNV Research Group (Lausanne)
were taking part in a larger research project on CNVs at
the 1q21.1 locus. Proband carriers were referred to the
study by clinical geneticists. The study was reviewed and
approved by the local ethics committee (CER-VD;
PB_2016-02137) and written informed consent was
obtained from participants or legal representatives before
investigation. Participants were assessed at the Lausanne
University Hospital, Switzerland.
Cohort demographics
Data from 123 participants, comprising 68 deletion and
55 duplication carriers, were analysed for this study and
compared with data from 70 familial controls. Participants
were grouped and analysed according to carrier status
(deletion, duplication and control) and age group (child <
18 years, adult ≥18 years) to avoid biasing against psy-
chopathologies which are more prevalent at specific life-
stages. For full details of participant demographics see
Suppl. Table S1. No significant age or gender differences
were observed between deletion carriers, duplication
carriers and controls either in the child or adult cohort
(Suppl. Tables S1 and S2).
Carrier status for the 1q21.1 deletion or duplication was
confirmed through clinical chromosome microarrays and/
or medical records. We only included carriers with a
deletion or duplication that spanned at least 80% of
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the typical distal locus (chr1:146,527,987–147,394,444
(hg19)), but not the nearby TAR locus (Suppl. Fig. S1 and
S2), based on information from clinical genetics reports or
in-house genotyping. Of the 123 CNV carriers, the
inheritance status was known for 86 participants (70%).
Seventy-three of these individuals had a ‘known inherited’
status (85%, with one parent with a confirmed 1q21.1
CNV carrier status), 13 individuals (15%) had a ‘known
de-novo’ status (both parents with negative genetic tests
for a 1q21.1 CNV).
Psychopathology and neurodevelopmental function
To assess general psychopathology in children (diag-
nosis as well as symptomatology), the Cardiff group used
the Child and Adolescent Psychiatric Assessment
(CAPA)11. Autism symptomatology was measured by the
Social Communication Questionnaire (SCQ)12. The
Strengths and Difficulties Questionnaire13 was used to
establish conduct problems, emotional problems, hyper-
activity problems, peer problems and prosocial function-
ing as well as a total SDQ score. Motor functioning was
measured by the Developmental Coordination Disorder
Questionnaire (DCDQ)14. Full methodological details
have already been reported elsewhere9.
Adult psychopathology was assessed using the Psy-
chiatric Assessment Schedule for Adults with Develop-
mental Disabilities (PAS-ADD)15. Psychotic symptoms
were assessed using the Structured Interview for Pro-
dromal Symptoms (SIPS)16. Adult participants who dis-
played psychotic symptoms on the SIPS were further
assessed using the Scale for the Assessment of Positive
and Negative Symptoms (SAPS) and (SANS), respec-
tively17. Adult participants in the Cardiff cohort also
completed the SCID-II, a semi-structured interview for
making DSM Axis II: Personality Disorder diagnoses.
However, in this paper we are not reporting frequencies of
personality disorders because this information was not
available in the other cohorts. All diagnoses were con-
firmed by a licensed psychiatrist based on face-to-face
interviews or review of the interview protocols. If the
PAS-ADD showed evidence of autistic symptoms, the
DISCO, a semi-structured interview, or the “Royal College
of Psychiatrists Diagnostic Interview Guide for the
Assessment of Adults with Autism Spectrum Disorder”
was used to confirm the diagnosis18,19.
The Lausanne CNV Research Group used the Diagnostic
Interview for Genetic Studies (DIGS)20. Each of the tools
used corresponded to the DSM-IV/5 criteria for psycho-
pathologies being assessed in this report. The Lausanne
control participants had no psychopathological assess-
ments and were therefore not included in the relevant
comparisons. Children were assessed using the ADOS21.
In the Simons VIP, children were assessed using the
ADOS21 and ADI-R22 (used for suspected ASD cases) and
the DISC (Diagnostic Interview Schedule for Children)23
or DISC-YC (Young Child Edition), for children between
3 and 624, and parent behaviour rating scales. Adults were
assessed using the ADOS, ADI-R (used for suspected ASD
cases up to age 26) and the self-report SCL-90-R25],
followed by a clinical interview. Diagnoses of control
participants were also based on the SCL-90-R (n= 23) or
self-report (n= 28).
All centres also collected information about seizure
history (separated into febrile and unprovoked seizures)
although this information was not available for most of
the controls.
Cognitive functioning
In Cardiff, general cognitive ability was assessed by
trained raters using the Wechsler Abbreviated Scale of
Intelligence (WASI)26. For the children, data were also
available for reaction time, sustained attention, spatial
planning, and spatial working memory as measured by the
Cambridge Neuropsychological Test Automated Battery
(CANTAB)27, and set-shifting ability as measured by the
Wisconsin Card Sorting Test (WCST)28. Adults recruited
by the Simons VIP group were also assessed using the
WASI, while children were assessed using the Differential
Ability Scales (DAS) cognitive battery29 (2.5 years and
older) or the Mullen Scales of Early Learning30 (all ages,
dependent upon developmental level, resulting in a ratio
IQ where applicable). The CNV Research Group used
Wechsler intelligence testing for all participants as pre-
viously described31.
Data analysis
Data analyses were conducted using SPSS v.23 (RRID:




The frequency of clinical phenotypes was analysed
separately for children and adults. We compared the
frequency of any DSM-IV/5 diagnosis between carriers
and controls to test whether copy number variation at the
locus is associated with a higher prevalence of psycho-
pathology. For children, neurodevelopmental (ASD,
ADHD, ID, social communication disorder and specific
learning disorder), anxiety, mood, conduct, eating and
substance use disorders were pooled across subcategories.
We also pooled diagnostic categories for adults (anxiety,
mood disorder, conduct disorder, neurodevelopmental,
psychotic and substance use disorders). Using a random-
effects logit model we tested for the effect of group status
(e.g. Deletion vs Control, or Duplication vs Control)
(independent variable) on the frequencies of psychiatric
diagnoses (Dependent Variable: 0=No Diagnosis,
Linden et al. Translational Psychiatry          (2021) 11:105 Page 3 of 10
1=Diagnosis Present) while adjusting for age, sex (Fixed
Effects) and FSIQ (only in children because of wider
availability of measures) (Random Effect). Control indivi-
duals from families with a participant with either a dele-
tion or a duplication were combined and comparisons for
both CNVs were conducted with the same control sam-
ple. For one comparison (adult duplication effect on
anxiety) we had to remove the covariate sex because all
anxiety cases (controls and duplication) were female.
Because our control sample consisted of family members
of the carriers, case-control pairs from the same family are
likely to be more similar because of shared genetic and
environmental background variation. We could not
always control for this because of collinearity (arising
from the pooling of controls and imbalance of control
recruitment across sites). Where it was possible, we ran
analyses including family ID as a random factor in our
models. We report results without family ID as default in
Tables 1 and 2, but have added the findings of models
including the effects of family ID in the footnotes of these
Tables, where these could be reliably computed.
Continuous variables
We conducted linear mixed-effect models for FSIQ,
VIQ and PIQ, with group status (deletion vs duplication
vs controls), age, and sex as fixed effects, and family as a
random effect to take into account relatedness between
1q21.1 CNV carriers and controls. Post hoc Tukey tests
were conducted to evaluate which groups differed for
FSIQ, VIQ and PIQ. Statistical analysis of the difference in
head circumferences between the participants with 1q21
deletion and duplication was conducted with t-test for
independent groups, following conversion of raw scores
to age-standardised Z-scores.
We transformed neuropsychiatric trait scores (only
available for the Cardiff children) using the Tukey
Ladder of Powers transformation to make the data fit the
normal distribution as closely as possible9. We then
standardised all transformed test scores into Z-scores
using the mean and SD of the control group as reference
—i.e., the difference in the individual’s score and the
mean score for the control group was divided by the SD
for the control group. We constructed these Z-scores so
that a negative score denoted a worse outcome. We used
linear mixed-effects models with test score as the out-
come and carrier status (deletion, vs duplication vs





The frequency of psychiatric disorders in the children
with 1q21 CNVs is documented in Table 1 and Fig. 1.
Both children with the deletion (OR= 7.11 (1.34–48.60),
p= 0.03) and those with the duplication (OR= 12.24
(2.62–74.84), p= 0003) had higher frequencies of any
psychiatric diagnosis compared to the family control
sample. The prevalence of any neurodevelopmental dis-
order (NDD, including ASD, ADHD, ID, social commu-
nication disorder and specific learning disorder) was 56%
in the deletion and 68% in the duplication carrier group as
compared to 0% in the family controls.
The most prevalent NDD was ADHD both in children
with the deletion (19/50 cases assessed for NDD; 38%)
and children with the duplication (21/44 cases assessed
for NDD; 47.7%) (Suppl. Table S3). The prevalence of any
anxiety disorder was also higher in the deletion (25%) and
duplication (23%) carrier groups as compared to the
controls (11%), but these differences did not reach sig-
nificance. Generalised anxiety disorder and specific pho-
bia were the most common diagnoses in both the deletion
and the duplication groups (Suppl. Table S4).
Children with 1q21.1 deletion had higher scores relative
to control siblings for ADHD traits as measured by the
CAPA (ADHD symptomatology, z=−2.85, p= 0.005)
and the SDQ (Hyperactivity subscale, z=−2.10, p=
0.002), with higher scores indicating higher difficulty
levels/psychopathology. Children with the 1q21.1 dupli-
cation had higher scores than control siblings for ADHD
traits as measured by the CAPA (ADHD symptomatology,
z−=−3.11, p= 0.005) and the SDQ (Hyperactivity sub-
scale, z=−2.38, p= 0.003), and traits of oppositional
defiance as measured by the CAPA (ODD symptomatol-
ogy, z=−1.50, p= 0.006) and the SDQ (Conduct sub-
scale, z=−2.08, p= 0.018). Comparing the two CNV
groups, children with the deletion had higher levels of
mood symptomatology (z difference=−0.56, p= 0.033),
and ODD symptomatology (z difference=−1.01, p=
0.008) than children with the duplication. Full results of
the CAPA scores are presented in the Supplementary
Material 2.
Adult sample
The frequencies of mental disorders in the adults with
1q21 CNVs are documented in Table 2 and Fig. 1.
Deletion carriers versus family controls Fifty-nine
percent of the carriers had at least one psychiatric
disorder compared to 28% in the control group (OR=
4.0, p= 0.03). The prevalence of any mood disorder was
higher in the deletion carrier group as compared to the
family controls (35% versus 9%, OR= 6.0, p= 0.02). No
differences were found for any of the other diagnostic
categories. The ORs were similar in the model with family
ID included although the difference in mood disorder was
no longer significant (from p= 0.02 to 0.14).
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Duplication carriers versus family controls Seventy-
three percent of the carriers (versus 28% of the family
controls) met criteria for any psychiatric disorder (OR=
6.0, p= 0.03). The prevalence of any mood disorder was
higher in the duplication carrier group as compared to
the family controls, (55% versus 9%, OR= 8.3, p= 0.02).
The prevalence of any anxiety disorder was also higher in
the duplication carrier group as compared to the family
controls (55% versus 16%, OR= 10.0, p= 0.01). No
differences were found for any of the other diagnostic
categories. The ORs were similar in the model with family
ID included although the difference in any psychiatric
diagnosis now only reached trend level (p= 0.06).
Seizure rates
Seven out of 36 children with deletions (19.4%) and 5/35
children with duplications (14.3%) had a history of
unprovoked seizures. History of febrile seizures was
reported for no child with deletion and 2/35 children with
duplications (6%). Figures in adults were too low to allow
for robust inferences but did not provide evidence for
increased seizure rates (Suppl. Table S5).
Cognitive function
IQ data is presented in Table 3. Full data on CANTAB
subscores are presented in the Supplementary Material 2.
Children
The three groups differed for FSIQ (F= 7.01, df= 2,
p= 0.002), PIQ (F= 7.62, df= 2, p < 0.001) and VIQ
(F= 4.37, df= 2, p= 0.016). Post hoc tests (Tukey) indi-
cated that deletion carriers had a lower FSIQ (p= 0.002),
PIQ (p < 0.001) and VIQ (p= 0.029) than controls and
similarly that duplication carriers had lower FSIQs, PIQs
and VIQs than controls (FSIQ: p= 0.025; PIQ: p= 0.035;
VIQ: p= 0.033). There were no IQ differences between
deletion and duplication carriers (FSIQ: p= 0.582; PIQ:
p= 0.274; VIQ: p= 0.996).
Children with 1q21.1 deletion had deficits relative to
control siblings in spatial cognition including spatial
planning (z=−1.46, p= 0.011), and spatial working
memory (z=−2.23, p= 0.009). Children with the 1q21.1
duplication also had deficits relative to control siblings in
spatial working memory (z=−2.71, p= 0.001). Children
with the deletion had greater deficits in sustained atten-
tion than children with the duplication (z difference=
−0.62, p= 0.020).
Adults
The three groups differed for FSIQ (F= 9.18, df= 2, p <
0.001), PIQ (F= 5.64, df= 2, p= 0.007) and VIQ (F=
5.77, df= 2, p= 0.006). Post hoc tests (Tukey) indicated
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(p= 0.002), PIQ (p= 0.014) and VIQ (p= 0.025) but that
there were no significant differences between duplication
carriers and controls (FSIQ: p= 0.168; PIQ: p= 0.590;
VIQ: p= 0.223). Moreover, there were no IQ differences
between deletion and duplication carriers (FSIQ:
p= 0.428; PIQ: p= 0.323; VIQ: p= 0.747).
Head circumference
Age-normalised head circumference data were available
for 35 deletion and 34 duplication carriers (Fig. 2). Stan-
dardised head circumference was markedly lower for
deletion vs. duplication carriers (t=−6.48 [95% CI=
−4.48−2.37], df= 66.4, p-value= 1.3 × 10−8).
Discussion
This is the largest and most detailed study to date
documenting the psychiatric and cognitive phenotype
associated with copy number variation at the 1q21 chro-
mosomal locus. We found a clear association of deletion
and duplication of the critical region of chromosome 1q21
with psychopathology both in children ascertained
through clinical genetics services and an adult group that
was mainly composed of parents of probands. As in pre-
vious studies, based on smaller samples, the main diag-
nostic groups of neurodevelopmental disorders were
ADHD and ASD. Association of both the deletion and the
duplication with ADHD- and ASD-related psycho-
pathology was also revealed through quantitative mea-
sures (CAPA and SDQ) in the Cardiff children sample.
However, the high prevalence of anxiety disorders in both
deletion and duplication carriers (previously only reported
for those with the deletion) [9] and the high prevalence of
mood and anxiety disorders in the high-functioning adult
group are novel findings. These findings and the recent
report of high prevalence of depression in participants of a
population cohort (UK Biobank) with 1q21 deletion32
underline the association of the 1q21 locus with psycho-
pathology beyond the classical neurodevelopmental
disorders.
We found no evidence for preponderance of certain
psychiatric syndromes in the deletion or duplication
carriers, which some of the previous, smaller studies had
suggested, in line with other studies highlighting com-
monalities across CNV dosage33. An implication of
comparisons between carriers of deletions and duplica-
tions across multiple CNVs is that normal function seems
to be supported by normal dosage of genes/proteins in the
region, and deviations in both directions can be damaging.
Furthermore, we found no evidence of psychiatric mirror
phenotypes such as increased vs. reduced risk, which has
been discussed for another CNV locus (22q11.2 deletion
vs. duplication)34.
Similarly, seizure frequencies were high in both children
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understudied topic in CNV research: however, a recent
study has indicated that the frequency of seizures in
young people with 22q11.2 deletion syndrome may be
higher than suspected35, indicating that individuals with
certain CNVs may need to be closely monitored and
particularly under certain circumstances (e.g., fever). The
one mirror phenotype of head size associated with this
locus6 was confirmed in our study. We found the deletion
Fig. 1 Diagnostic overlap of mental disorders. Venn diagrams showing number of main diagnoses (as well as multiple diagnoses: participants
placed in the respective intersections) in children and adults with any psychiatric diagnosis.
Table 3 Measures of intelligence for children and adults with 1q21.1 deletion or duplication and family controls.
Mean VIQ* (SD) {range} Mean PIQ* (SD) {range} Mean FSIQ* (SD) {range}
Children (n= 80)
Deletion (n= 33) 83.3** (17.9) {56–120} 85.3** (13.8) {59–114} 82.4** (15.4) {58–112}
Duplication (n= 30) 83.8** (19.0) {49–123} 90.3** (17.6) {57–126} 86.0** (18.3) {53–128}
Controls (n= 17) 97.6 (12.3) {75–115} 102.5 (9.0) {86–122} 99.9 (10.6) {83–121}
Adults (n= 44)
Deletion (n= 11) 87.8** (18.8) {63–113} 95.7** (12.1) {73–117} 90.6** (15.4) {70–116}
Duplication (n= 9) 95.6 (13.5) {73–111} 106.0 (14.0) {82–125} 100.8 (12.6) {81–115}
Controls (n= 24) 106.9 (14.8) {78–128} 111.7 (12.9) {89–140} 111.5 (12.9) {83–134}
*Significant group difference (F-test) at p < 0.05.
**Significantly lower than in controls (Tukey post hoc tests) at p < 0.05. For further details see ‘Results’ section.
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was associated with smaller and the duplication with
larger head circumference.
We initially hypothesised that both 1q21.1 deletions and
duplications would result in cognitive impairment; however,
the cognitive abilities in our study varied widely between the
age-categories. Although each carrier group (except for the
adults with a duplication) displayed significantly lower levels
of cognitive ability than controls, the mean scores in the
adult carriers were in the normal range, reflecting the
notion that the child and adult carriers recruited to this
study may fall in different parts of the 1q21.1 functional
spectrum based upon method of ascertainment.
Like other neurodevelopmental CNVs, including
22q11.2 deletion syndrome36, the effect of 1q21 deletion
and duplication on psychopathology is pleiotropic. This
suggests that pathogenic CNVs are associated with cog-
nitive impairment and psychological dysfunction9, per-
haps through alterations in brain development37, rather
than a specific psychiatric syndrome. Although the spec-
trum of phenotypes includes intellectual disability, and
both 1q21 deletion and duplication are associated with
reductions in mean IQ and educational attainment4, the
present study shows that psychopathology in CNV car-
riers at this locus is not confined to those with a low IQ.
Even the adult group, with a mean full-scale IQ in the
average range, had high prevalence of psychopathology,
mainly anxiety and mood disorders. Beyond this dis-
sociation of intellectual impairment and psychopathology,
our study reveals two subgroups of carriers of CNVs at
1q21: an intellectually impaired group that is referred to
clinical genetics services in childhood because of devel-
opmental delay and/or physical abnormalities and has a
high prevalence of neurodevelopmental disorders, but
also of anxiety disorders, and a group with only subtle
intellectual/educational impairment (but high prevalence
of anxiety/mood disorders) which is generally not recog-
nised unless they are referred for genetic testing because
of their children. Similar patterns likely exist for other
neurodevelopmental risk factors with variable penetrance,
even those associated with recognised clinical syndromes
such as 22q11.2 deletion. The mechanisms underlying this
variable penetrance of pathogenic neurodevelopmental
CNVs are still poorly understood and likely include both
genetic (oligogenic and polygenic)38 and environmental
modifiers. Large and multigenerational cohorts of CNV
carriers are particularly suited to the study of modifying
effects because they allow for the comparison of probands
and their (generally less severely affected) parents and
extended family members.
The experience of caring for a mentally ill child may
contribute to a higher prevalence of stress-related dis-
orders in parents. However, a recent large-scale study into
the (sub)clinical symptoms of parents of children and
adolescents with psychopathology found lower fre-
quencies (depressive symptoms: 12.8% for fathers, 14.6%
for mothers; anxiety: 6 and 7.2%39) than the present study,
which suggests a genetic contribution to the psycho-
pathology of the adult carriers. In addition to the
importance for the integrated clinical care for families
affected by CNVs at 1q21, these findings also have
implications for translational neuroscience, highlighting
the need to model the anxious phenotype in animal
models of this locus and to identify the responsible genes.
The 1q21 critical region contains several genes that are
expressed in the brain, including Hydrocephalus-inducing
homologue 2 (HYDIN2) and three Notch homologue 2
N-terminal-like (NOTCH2NL) genes. It has recently been
proposed that NOTCH2NL is crucial for the effects on
cortical development40. Another proposed genetic
mechanism for the effects on head/brain size is related to the
Olduvai protein domain (formerly called DUF1220 domain).
Sequences coding for this protein domain (average amino
acid length ~65) are predominantly found in the 1q21 locus,
primarily clustered in Neuroblastoma breakpoint family
(NBPF) genes in close proximity to the NOTCH2NL genes41.
The human lineage-specific increase in copy number of
sequences coding for these domains has been linked with
the anthropoid brain expansion42, and individual differences
in copy number were associated with brain size in people
with 1q21 deletion43. Because of the SNP array used, this
study focussed on large CNV’s present at this locus and
further studies, including sequencing and high resolution
CNV analysis of large cohorts, will be necessary for a full
elucidation of these genotype-phenotype relationships.
Limitations
The collaborations reported in this study were estab-
lished following the assessment of participants and hence
there is some discrepancy in the assessment measures
used by each research centre. Another limitation is the
relatively small number of family controls, particularly in
the children group. We had to use the same control
sample for both deletion and duplication carriers, which
resulted in difficulties controlling effects for familiality.
Fig. 2 Distribution of head circumference. Age-normalised Z-scores
for head circumference are plotted for 35 participants with 1q21
deletion (27 children and eight adults, age range 2–51) and 34
participants with 1q21 duplication (25 children and nine adults, age
range 1–68).
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Implications
The results of the present study support the need for more
extensive genetic testing in psychiatry because it is likely that
a considerable number of users of mental health services
carry an undiagnosed genetic variant. A recent study in
patient groups with intellectual disability and comorbid
mental disorder identified recognised pathogenic CNVs in
~10%44. If genetic testing were to be offered routinely for
this patient population in mental health services, this would
not only inform their clinical care but also provide much-
needed information about the frequency and severity of
neurobehavioral challenges associated with CNVs.
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